Surgery

Roseman University College of Nursing Launches Doctoral Program for Nurse Anesthetists

Retrieved on: 
Monday, March 4, 2024

The College of Nursing at Roseman University of Health Sciences today announced its new Doctor of Nursing Practice in Nurse Anesthesia (DNPNA) program to address the national demand for Certified Registered Nurse Anesthetists (CRNAs).

Key Points: 
  • The College of Nursing at Roseman University of Health Sciences today announced its new Doctor of Nursing Practice in Nurse Anesthesia (DNPNA) program to address the national demand for Certified Registered Nurse Anesthetists (CRNAs).
  • The program, approved by the Council on Accreditation of Nurse Anesthesia Educational Programs (COA), is accepting applications for an inaugural class starting in July 2024.
  • “Roseman’s DNPNA students will learn how to administer anesthesia and deliver anesthesia-related services independently and as part of an interprofessional team.
  • “We are delighted to launch this new program to prepare nurses for one of the most in-demand and critical roles in health care,” says Brian Oxhorn, PhD, RN, dean of Roseman University College of Nursing.

NVISION Eye Centers' Subsidiary, NVISION Clinical Research, Rapidly Expands Under New Leadership

Retrieved on: 
Monday, March 4, 2024

NVISION Eye Centers, a renowned national leader in comprehensive eye care services, proudly announces the remarkable expansion of its subsidiary, NVISION Clinical Research, LLC.

Key Points: 
  • NVISION Eye Centers, a renowned national leader in comprehensive eye care services, proudly announces the remarkable expansion of its subsidiary, NVISION Clinical Research, LLC.
  • NVISION Clinical Research, LLC, an integral member of the NVISION family, is exclusively dedicated to facilitating clinical trial opportunities to patients treated by NVISION ophthalmologists.
  • With more than 40 physician investigators across 20 clinical trial sites, NVISION Clinical Research, LLC operates one of the largest ophthalmology-specialized clinical trial site networks nationwide.
  • As a seasoned executive in the clinical research arena, Dr. Gibertini is ideally positioned to steer NVISION Clinical Research, LLC through its next phase of growth.

Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini

Retrieved on: 
Monday, March 4, 2024

The study is being conducted in Australia and is enrolling healthy individuals 18 to 55 years of age.

Key Points: 
  • The study is being conducted in Australia and is enrolling healthy individuals 18 to 55 years of age.
  • Data from this Phase 1 clinical study will support future development across multiple indications.
  • Preclinical studies using models of AKI have demonstrated pretreatment with Gemini can reduce the severity and duration of AKI.
  • The start of this study is an important step toward bringing a potential new therapy for these unmet needs.”

Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2023 Financial Results on March 21, 2024

Retrieved on: 
Monday, March 4, 2024

Apyx® Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the fourth quarter and fiscal year 2023 will be released before the market opens on Thursday, March 21st.

Key Points: 
  • Apyx® Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the fourth quarter and fiscal year 2023 will be released before the market opens on Thursday, March 21st.
  • Management will host a conference call at 8:00 a.m. Eastern Time on March 21st to discuss the results of the quarter and year, and to host a question and answer session.
  • To listen to the call by phone, interested parties may dial 877-407-8289 (or 201-689-8341 for international callers) and provide access code 13744178.
  • Participants should ask for the Apyx Medical Corporation Call.

LivaNova Announces Proposed Private Offering of $300 Million of Convertible Senior Notes

Retrieved on: 
Monday, March 4, 2024

The interest rate, conversion rate and other terms of the notes are to be determined upon pricing of the offering.

Key Points: 
  • The interest rate, conversion rate and other terms of the notes are to be determined upon pricing of the offering.
  • If the initial purchasers of the notes exercise their option to purchase additional notes, LivaNova expects to enter into additional capped call transactions with the option counterparties.
  • The cash exchangeable senior notes were issued by LivaNova USA, Inc. and are guaranteed by LivaNova.
  • In connection with the issuance of the cash exchangeable senior notes, LivaNova USA, Inc. entered into capped call transactions with certain financial institutions.

HCA Healthcare Named as One of the 2024 World’s Most Ethical Companies by Ethisphere

Retrieved on: 
Monday, March 4, 2024

HCA Healthcare has been recognized 14 times and is one of only four honorees in the Healthcare Providers category this year.

Key Points: 
  • HCA Healthcare has been recognized 14 times and is one of only four honorees in the Healthcare Providers category this year.
  • “Being named as one of the World’s Most Ethical companies for the 14th time is a reflection of our commitment to the values on which HCA Healthcare was founded,” said Sam Hazen, CEO of HCA Healthcare.
  • In 2023, colleagues logged more than 180,000 volunteer hours and gave $16.9 million in giving with HCA Healthcare matching.
  • In 2023, HCA Healthcare and the HCA Healthcare Foundation gave more than $43 million to community organizations across the nation.

Western Dental Brings Affordable Dental Care to Reseda

Retrieved on: 
Monday, March 4, 2024

Western Dental & Orthodontics, a member of the Sonrava Health family of wellness companies, today announced the opening of its Reseda dental office, which will be co-located with a LooksBrite Eye Center, opening soon.

Key Points: 
  • Western Dental & Orthodontics, a member of the Sonrava Health family of wellness companies, today announced the opening of its Reseda dental office, which will be co-located with a LooksBrite Eye Center, opening soon.
  • The new state-of-the-art dental office includes 14 treatment rooms, offering comprehensive dental care – including general and pediatric dentistry, oral hygiene, orthodontics, dental implants and oral surgery – creating a convenient, full-service “dental home” for patients.
  • "By combining vision and dental care in a single location, we're providing a holistic care solution for patients in the community,” says Dr. Peter Truong, Regional President.
  • Prioritizing dental care in communities such as these is an investment in the future of every individual."

LivaNova to Present at the Barclays Global Healthcare Conference

Retrieved on: 
Monday, March 4, 2024

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Barclays Global Healthcare Conference in Miami, Florida.

Key Points: 
  • LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Barclays Global Healthcare Conference in Miami, Florida.
  • The presentation will take place at 10:45 a.m. Eastern Time on Tuesday, March 12.
  • The discussion will be available to all interested parties who register to attend the webcast, which is accessible via www.livanova.com/events .
  • A replay will be available on the LivaNova website within 24 hours after the live presentation for 90 days after the event.

Vicarious Surgical Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Monday, March 4, 2024

R&D expenses for the fourth quarter of 2023 were $8.5 million, compared to $11.9 million in the fourth quarter of 2022.

Key Points: 
  • R&D expenses for the fourth quarter of 2023 were $8.5 million, compared to $11.9 million in the fourth quarter of 2022.
  • General and administrative expenses for the fourth quarter of 2023 were $5.9 million, compared to $6.9 million in the fourth quarter of 2022.
  • Sales and marketing expenses for the fourth quarter of 2023 were $1.2 million, compared to $1.8 million in the fourth quarter of 2022.
  • ET on Monday, March 4, 2024, to discuss its fourth quarter and full year 2023 financial results.

Evolus Announces Results from European Head-to-Head Filler Trial

Retrieved on: 
Friday, March 1, 2024

Evolus remains on track for the global commercial launch of the first-generation Cold HA Technology in 2025.

Key Points: 
  • Evolus remains on track for the global commercial launch of the first-generation Cold HA Technology in 2025.
  • The filler line will be branded Evolysse™ in the US and Estyme® in the UK and Europe.
  • The Evolysse™/Estyme® Lift filler will be positioned as the most versatile and highest volume filler in the product line.
  • An archived webcast can also be accessed on the Investor Relations page of the Evolus website at www.evolus.com .